<div id="readability-page-1"><div>(Alliance News) - Hutchmed China Ltd on Wednesday said it has begun the global phase one clinical development programme for its targeted cancer therapy for patients with solid tumours.The global commercial-stage biopharmaceutical company, headquartered in Hong Kong, said the first in-human trial is for HMPL-A251, an antibody-targeted therapy conjugate. The programme, which has study sites in the US and China, kicked off with the first patient receiving the first dose on Tuesday. HMPL-A251 is the first clinical-stage candidate derived from Hutchmed's next-generation ATTC platform, the company said. ATTCs combine chemotherapy and targeted therapies. The platform enables the development of drug candidates for diverse cancer types, Hutchmed said. The study will evaluate HMPL-A251 in adult patients with unresectable, or not surgically removable, advanced or metastatic HER2-expressing solid tumours. HER2 is a receptor protein, which in cancer cells promotes excessive cell growth.The study is divided into two parts: phase one is dose escalation, and phase 2a is dose expansion and optimisation. In preclinical studies, HMPL-A251, which links the antibody and the payload, &#34;exhibited superior anti-tumour efficacy and tolerability&#34;, compared to co-administration, Hutchmed said. Shares in Hutchmed China rose 1.0% to 202.00 pence on Wednesday afternoon in London. By Roya Shahidi, Alliance News reporterComments and questions to newsroom@alliancenews.comCopyright 2025 Alliance News Ltd. All Rights Reserved.</div></div>

和黃醫藥

和黃醫藥已啓動 HMPL-A251 的全球一期臨牀開發項目，這是一種針對實體腫瘤的靶向癌症治療。該項目包括美國和中國的研究地點，首位患者已接受治療。HMPL-A251 源自和黃醫藥的 ATTC 平台，結合了化療和靶向治療。該研究將評估該療法在 HER2 表達腫瘤中的療效。公告發布後，和黃醫藥的股價上漲了 1.0%

和黃醫藥啓動 ATTC 候選藥物的臨牀開發